Knight Therapeutics Relaunches AKYNZEO® in Canada
Knight Therapeutics Inc. has assumed full commercial activities for AKYNZEO® (netupitant/palonosetron capsules) in Canada. The drug is used to prevent nausea and vomiting associated with cancer chemotherapy.
Montreal, Canada – Knight Therapeutics Inc. (TSX: GUD) announced it has assumed full commercial activities for AKYNZEO® (netupitant/palonosetron capsules) in Canada and is relaunching the product.
The company and Helsinn Healthcare SA entered into an exclusive license, distribution, and supply agreement in May 2022, covering oral and intravenous AKYNZEO® and ALOXI® in Canada, Brazil, Argentina, Uruguay, and Paraguay.
AKYNZEO® is approved in Canada for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy. It is also indicated for the prevention of acute nausea and vomiting associated with moderately emetogenic cancer therapy when not adequately controlled by a 5-HT3 receptor antagonist alone in adults.
"We are excited to take over Canadian commercialization of AKYNZEO®, an innovative once-per-cycle fixed dose, dual combination antiemetic that offers a leading and guideline-recommended prophylactic treatment for chemotherapy induced nausea and vomiting," said Samira Sakhia, President and CEO of Knight Therapeutics. "AKYNZEO® builds upon Knight’s growing Canadian oncology portfolio, increasing our presence in this important therapeutic area."